OBI Pharma's OBI-902 IND Application Cleared for Phase 1/2 Trial in Advanced Solid Tumors

OBI Pharma announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OBI-902, a Trop-2...
Home/KnloSights/Clinical Trial Updates/OBI Pharma's OBI-902 IND Application Cleared for Phase 1/2 Trial in Advanced Solid Tumors